The Impact of the Gene Recurrence Score on Chemotherapy Prescribing in ER Positive, Lymph Node Positive Early Stage Breast Cancer

A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.

NCT01485926 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX

NCT06723990 ·Status: RECRUITING

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy

NCT04928261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Phase II Trial for Large ER-Negative Breast Cancers

NCT01869192 ·Status: COMPLETED ·Phase: PHASE2

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

NCT04829604 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

S9719 Gene Damage Following Chemotherapy in Women With Stage II or Stage III Breast Cancer

NCT00003095 ·Status: COMPLETED

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

NCT00897026 ·Status: COMPLETED

Study of Neoadjuvant Chemotherapy of Breast Cancer

NCT00830544 ·Status: UNKNOWN ·Phase: PHASE2

Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer

NCT03080428 ·Status: WITHDRAWN ·Phase: NA

Locoregional Recurrence After Neoadjuvant Versus Adjuvant Chemotherapy

NCT06299930 ·Status: COMPLETED

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

NCT02101385 ·Status: COMPLETED ·Phase: PHASE2

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

NCT01548677 ·Status: COMPLETED ·Phase: PHASE2

A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)

NCT00759785 ·Status: COMPLETED ·Phase: PHASE1

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

NCT00432172 ·Status: COMPLETED ·Phase: PHASE2

CharactHer. ICORG 12-09, V3

NCT01722890 ·Status: TERMINATED

A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1

NCT00306631 ·Status: COMPLETED ·Phase: PHASE2

Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer

NCT06446882 ·Status: RECRUITING ·Phase: NA

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

NCT03412643 ·Status: UNKNOWN ·Phase: PHASE2

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

NCT03373708 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

Identification of Early Markers of Response and Resistance to Trastuzumab

NCT01834950 ·Status: COMPLETED ·Phase: NA

Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy

NCT03638648 ·Status: UNKNOWN ·Phase: PHASE2

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

NCT00038402 ·Status: COMPLETED ·Phase: PHASE3

An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)

NCT02658461 ·Status: COMPLETED

An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer

NCT00291122 ·Status: COMPLETED

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

NCT00336791 ·Status: COMPLETED ·Phase: PHASE3